WO2004096275A1 - サイトカイン誘導用具及びサイトカイン誘導方法 - Google Patents
サイトカイン誘導用具及びサイトカイン誘導方法 Download PDFInfo
- Publication number
- WO2004096275A1 WO2004096275A1 PCT/JP2004/005986 JP2004005986W WO2004096275A1 WO 2004096275 A1 WO2004096275 A1 WO 2004096275A1 JP 2004005986 W JP2004005986 W JP 2004005986W WO 2004096275 A1 WO2004096275 A1 WO 2004096275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytokine
- inducing
- blood
- carrier
- induction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a cytokine induction tool and a method for inducing cytokines, which are used for cytokine induction therapy or the like and can effectively induce cytokines.
- Site force is a general term for a wide variety of intercellular communication factors.
- cytokines include interferon ⁇ , interferon] 3, interferon ⁇ (IF ⁇ - ⁇ ), interleukin 1 to interleukin 27, tumor necrosis factor-1 (Tum or Necrosis Factor), TNF— o;), tumor death factor j3 (Tum or Necrosis Factor—), transforming growth factor ⁇ v T ransforming G rowthactor— ⁇ )> transforming growth factor-1) 3 (T ransforming G rowth Factor — iS TGF—; 3), and various cell growth factors (Clinical Immunity Vol. 27 Special Extra Issue 1995) Clinical Immunity Vol. 36, 39-44, 2001, Clinical Immunity Vol. 39, 189-200, 2003).
- Cytokines have various activities in vivo and are known to be involved in various diseases.
- cytokine-inducing therapy for inducing the activity of cytokines in vivo to treat diseases has been performed.
- cytokine induction therapy a patient is administered a cytokine inducer and Induces cytokines in the body.
- cytokine-inducing substances used in such cytokine-inducing therapy.
- microbial-derived OK-432, BCG, bestatin, Maruyama vaccine, or romuritide are known, and as site-inducing substances derived from basidiomycetes, krestin, lentinan, or schizophyllic. Runs and the like are known.
- OK-432, BCG, etc. induce cytokines such as interleukin 1 and interferon ⁇ from blood and the like (Gifu Univ. 43: 166-177, 19). 1995, Molecular medicine Vol. 36, extra edition, 220-229, 1999).
- cytokine induction therapy there is a problem that it is difficult to induce a sufficient amount of cytokine in a living body S, and it is difficult to induce a strong effect.
- the dose of a cytokine inducer increases, side effects increase, and there is a problem that treatment cannot be effectively performed.
- Japanese Patent Application Laid-Open No. 61-2777628 discloses a leukocyte stimulating material for cancer treatment comprising OK-432, which is a kind of streptococcus, bound by an insoluble carrier covalent bond. It induces tumor-damaging cells, and this prior art document does not describe at all a cytokine-inducing tool and a cytokine-inducing method.
- blood bags used for blood transfusion are used only for storing and preserving blood or blood components.
- sitekine induction tools or methods for inducing tokine production there are no known sitekine induction tools or methods for inducing tokine production. Disclosure of the invention
- an object of the present invention is to provide a novel site-kine guidance tool and a site-force-in guidance method that can more effectively induce a site-kine compared to conventional site-force-in induction therapy.
- the present invention is a kinetics-inducing tool and a kinetics-inducing method comprising a kinetics-inducing agent and a carrier made of a water-insoluble porous material.
- the carrier is preferably an induction enhancer that enhances the site force-inducing action of the site force-inducing agent. Furthermore, it is preferable that the induction enhancer that enhances the cytokine induction action enhances induction of IFN-y.
- the inventors of the present invention have developed a cytokin induction tool including a carrier made of a water-insoluble porous material together with a cytokine inducer, or a cytokine induction tool made of an insoluble carrier having the cytokine inducer immobilized thereon.
- a cytokin induction tool including a carrier made of a water-insoluble porous material together with a cytokine inducer, or a cytokine induction tool made of an insoluble carrier having the cytokine inducer immobilized thereon.
- the present inventors have found that they show remarkably high cytokine induction, and thus completed the present invention.
- the present invention will be described in detail.
- the sitekine-inducing device of the present invention contains a sitekine-inducing agent and a carrier made of a water-insoluble porous material.
- the carrier is not particularly limited as long as it is made of a porous material insoluble in water.
- the carrier is made of a metal, an organic substance, an inorganic substance, or the like, and is preferably made of an organic material, more preferably a polymer material. .
- Examples of the metal include gold or a gold alloy, silver or a silver alloy, titanium or a titanium alloy, and stainless steel.
- Examples of the inorganic substance include activated carbon, glass or glass derivatives, Examples thereof include a silica composition, alumina, and hydroxyapatite.
- Examples of the organic material or the polymer material include cellulose, agarose, dextran, polystyrene, acrylester, polyethylene terephthalate, Nymouth, polyvinyl alcohol, Materials such as polysulfone, polyamide, polyacrylonitrile, polyethylene, polyurethane, polypropylene, and polyester can be used.
- polystyrene-based material examples include dibutylbenzene-styrene copolymer, and examples of the acrylester-based material include polymethyl methacrylate and polyhydroxyshethyl methacrylate. Is mentioned.
- a carrier made of a polystyrene-based or acrylic ester-based polymer material is preferable.
- the carrier is nonpolar and may be hydrophobic.
- a polystyrene polymer material or the like can be used as the carrier.
- hydrophilicity can be imparted to the surface of these carriers by surface modification or surface coating.
- the above-mentioned carrier may be made of a material having no strongly ion-exchangeable functional group or hydrophilic functional group and having a strongly hydrophobic surface. More preferably, it is made of a polymer material made of styrene, which does not have an ion exchange functional group or a hydrophilic functional group, and is a polymer material using a cross-linking agent such as divinyl benzene in styrene. It is particularly preferred that it consists of
- the shape of the carrier is not particularly limited, and for example, a known shape such as a fiber shape, a nonwoven fabric shape, a sponge shape, a particle shape, a film shape, and a hollow fiber shape can be used.
- a preferable lower limit is 50 ⁇ m and a preferable upper limit is 2 mm in a particulate form, and a fiber diameter is preferably 10 ⁇ m or less in a fibrous form, and preferably 5 ⁇ m or less. More preferably, there is.
- the carrier is fibrous, it is preferably made of a nonwoven fabric, and the fiber diameter is preferably 3 ⁇ m or less.
- the carrier of the present invention is it is considered preferable to use a carrier to which leukocytes do not adsorb, whereas the carrier of the present invention is It is preferable to use a material that adsorbs leukocytes and the like.
- the material that adsorbs leukocytes and the like include polystyrene, acrylic ester, polyesterol, nylon, polyvinyl alcohol, and cellulose acetate. Examples include a polymer material composed of a cellulose material and a glass material.
- the carrier is preferably made of a porous polymer material.
- the shape of the carrier various shapes such as spherical or non-spherical can be used, and the shape is not particularly limited.
- the non-spherical shape include a pellet, a column, a cylinder, a crush, a fiber, a sponge, a hollow fiber, and a sheet.
- a material in which the porous material is provided by coating or the like on the inner surface of the container or the above shape may be used.
- the surface area of the porous polymer material is preferably 40 Om 2 / g or more, the pore volume is preferably 0.5 mL / g, and the average pore diameter is a lower limit. Is preferably 20 A and the upper limit is 800 A.
- porous polymer materials can be roughly classified into a gel type having a standard gel structure and an MR type having a giant network structure (Maeroreticular structure). Also, simply styrene and divinylbenzene Porous resins and the like obtained by polymerization using a cross-linking agent such as above are called gel-type porous resins because they are nearly transparent and exhibit a gel structure.
- a physically porous resin or the like can be produced, and such a resin is called an MR type or a porous type porous resin.
- MR-type or porous-type with large pores (macropores) deep inside the particles can be obtained. Particles can be made.
- the particulate porous polymer material examples include strongly acidic cation exchange resin, weakly acidic cation exchange resin, strongly basic anion exchange resin, weakly basic anion exchange resin, synthetic adsorbent, and the like.
- Examples thereof include those made of a chelate resin and the like.
- These porous particles can be obtained by a known method. For example, they are produced as a spherical polymer by subjecting raw material monomers to suspension polymerization in water using a suitable suspension stabilizer such as gelatin.
- a compound having an ethylenic double bond such as styrene, biertoluene, ethyl acrylate, methyl methacrylate, and Atari-mouth ethryl is used, and dibutylbenzene, ethylene dimethacrylate, etc.
- a crosslinker which is a polyfunctional monomer, is added, and a crosslinked polymer is obtained using a polymerization initiator such as benzoyl peroxide or azobisisobutylnitrile in the presence of a porogen.
- porous particles include, for example, DIAION (registered trademark) manufactured by Mitsubishi Chemical Corporation, Amberlite manufactured by Rohm and Haas, and Dowex manufactured by Dow Chemical.
- a spherical resin with cross-linking can be made by suspending monomers of styrene and dibutylbenzene (crosslinking agent) in water and polymerizing them. At this time, an appropriate solvent that can dissolve the monomers is used. When added, phase separation is induced in the course of polymerization, and as a result, a polymer material having a porosity in a range that can be measured by the following pore distribution measurement method is produced.
- a porous polymer material having a giant network structure is more preferable.
- the pore distribution of the above-mentioned macro network structure preferably has a lower limit of 2 A and an upper limit of 2000 A, and more preferably 30 OA.
- the pore distribution can be defined by a generally used method, and can be represented by, for example, a pore diameter occupying 5 to 95% of the pore volume.
- the pore distribution can be measured by a conventionally used general test method. Examples of such test methods include a mercury intrusion method, a gas adsorption method, and a bubble point method.
- a mercury intrusion method a measuring device generally called a mercury intrusion porosimeter is used.
- the principle is that the sample is placed in a container that can be vacuum-processed, and the sample is covered with mercury after a pretreatment to remove water and various gases from the fine pores.
- pressure is applied to the entire mercury, the mercury loses its escape and enters the fine pores in the surface of the sample. The higher the pressure, the more mercury enters the small pores (ie, the pressure and the size of the pores are inversely proportional).
- a graph (pore distribution curve) of the relationship between the axis) and the pore volume (vertical axis) can be obtained.
- a gas such as nitrogen 'helium' krypton is generally used to degas the sample with a vacuum device and then apply a constant pressure or a certain amount of gas to the sample container, as in the previous porosimeter. Then, gas molecules are adsorbed on the surface of the sample.
- the mercury intrusion method the force of mercury entering through a large hole S
- the gas adsorption method the gas begins to be adsorbed in a small hole.
- the bubble point method is generally a method of measuring the pore distribution of through-holes, and is suitable for filters and nonwoven fabrics.
- the Freon liquid that has adhered to the large hole at a certain pressure is blown off and blows off.
- the gas then suddenly flows upward through the hole. If more gas is applied to the sample, the gas will flow out of it at a higher pressure than the first time, and the slightly smaller perfluorocarbon solution will fly as bubbles.
- the method for measuring the pore distribution is not limited to the above method, but may be another method capable of measuring the pore distribution.
- cytokine inducer examples include bacteria such as BCG, BCG—CWS, PPD, No cardia_CWS, OK—432, and muramyldipeptide, and their components; PSK :, lentinan, and schizophyllan Polysaccharides; polymers such as poly I: C, poly A: U; and chemical substances such as LeV amisole, DNCB, Azi mexon, Tilorone, and Bestatin.
- cytokine inducer not only the physiologically active substances described above, but also bacterial cells, bacterial components, acid-fast bacilli, streptococci, actinomycetes, peptides, nucleic acids, proteins, sugar components, lipids, prostaglandins, arachidonic acid Various proteins such as metabolites and Keyhole Limpet Heraocyanin (KLH) can also be used as a cytokine inducer.
- KLH Keyhole Limpet Heraocyanin
- cytokine inducers bacterial cells and / or components derived from the bacterial cells are preferred.
- acid-fast bacilli and components derived from acid-fast bacilli are more preferred, and Mycobacterium tuberculosis-components derived from Mycobacterium tuberculosis are particularly preferred.
- BCG, an attenuated strain of M. bovis, and its derived components are also particularly preferred.
- cytokine inducer streptococcus and a component derived from Z or streptococcus are also preferable.
- the cytokine inducer alone cannot sufficiently exert its ability to induce cytokines, it can also exert its activity to induce cytokines when used in combination with the above carrier. Therefore, as the cytokine inducer in the present invention, various substances can be used in addition to the conventionally used cytokine inducer.
- cytokine inducer on the surface of the carrier, known methods such as physical adsorption, covalent bonding, and ionic bonding can be used.
- covalent bond or the like it is preferable to introduce a spacer having an arbitrary length into the bond between the above-mentioned site force-inducing agent and the above-mentioned carrier, if necessary.
- the site force-inducing agent is a cell or the like
- various pretreatments such as a cell washing operation, a crushing operation, and a component fractionation operation may be performed before immobilization, if necessary.
- the above-mentioned site force-inducing agent is a viable bacterium, etc., as necessary, before immobilization, at the same time as immobilization, or after immobilization in order to further enhance safety
- the bacteria may be killed by various methods such as heat treatment, 'chemical treatment', radiation treatment, and gas sterilization.
- the above-mentioned heat treatment includes, for example, an autoclave treatment
- the above-mentioned chemical treatment includes, for example, a daltaraldehyde treatment, a formalin treatment, or an ethanol treatment
- the above-mentioned radiation treatment includes, for example, ⁇
- the gas sterilization treatment includes, for example, ethylene oxide gas treatment.
- cytokine inducer those modified with a protein denaturant are preferably used.
- the protein denaturing agent include various solvents such as daltar aldehyde, formalin, and ethanol, and a surfactant.
- heat treatment and the like also exert a protein denaturing action, heat treatment and the like in an aqueous solution are also included in the above protein denaturants.
- Holmali More preferred is a cytokine-inducing agent modified with a protein.
- cytokine inducer is a microorganism such as BCG
- a functional group such as a carboxyl group, an amino group, and / or an epoxy group of the carrier is provided via an amino acid or a sugar component of a cell surface outer wall component.
- spacers of various chain lengths and structures can be introduced as necessary.
- the cytokine inducer is a microorganism such as BCG in which the outer cell layer is covered with lipid or the like
- the lipid may be washed and removed if necessary, and then bound to the functional group of the carrier. Good.
- a physical adsorption method is preferable.
- the carrier has a hydrophobic surface and the cytoinducer is BCG, it can be immobilized by physical adsorption.
- the above-mentioned cytokine inducer is a microorganism or a component thereof and the surface thereof is charged, it can be immobilized on a carrier having the counter electrode charge on the surface by physical adsorption.
- the use ratio of the above carrier is not particularly limited, but when used as a particulate carrier, the lower limit is 0.02% and the upper limit is about 80% as the volume of the carrier relative to the blood volume, and the preferable lower limit is Is 0.1% and the preferred upper limit is around 50%.
- the use ratio of the above cytokine inducer is not particularly limited.
- the lower limit is 0.001 mg / mL in dry weight and the upper limit is 10 mg in terms of the concentration added to blood in blood. It is preferably / ml.
- the site force inducer is OK-432
- the lower limit of the concentration to be added to blood is preferably 0.0001 KE / mL
- the upper limit is preferably 10 KE / mL.
- the in-guidance device is also one of the present invention.
- the cytokine-inducing device of the present invention contacts the cytokine-producing cells in the container, whereby the cytokine is effectively induced.
- the lower limit of the contact temperature is preferably 15 ° C
- the upper limit is preferably 42 ° C, whereby the induction of the site force can be more effectively induced.
- the carrier and the cytokine inducer may be mixed in advance and contacted with cells that produce cytokines, or may be individually contacted with cells that produce cytokines. .
- the structure of the container is not particularly limited. However, as schematically shown in FIG. 1, the container comes into contact with the blood or the like introduction portion 1 and the site force-inducing device.
- a container 3 provided with an outlet 2 for guiding blood 4 and the like out of the container is preferable.
- a column-shaped container, a blood bag-shaped container, and the like are more preferable, and a blood bag-shaped container and the like are more preferable.
- the time required for the carrier and / or the site-inducing agent to come into contact with blood or blood components in the container can be arbitrarily selected. Can be guided.
- the guide force-inducing device of the present invention prevents the carrier and / or cytokine inducer from being mixed into blood or the like when blood or the like, which has been brought into contact with the carrier and / or the site force-inducing agent, is led out of the container. It is more preferable that the outflow prevention mechanism is provided.
- the carrier and / or the cytokine-inducing agent outflow prevention mechanism 5 may be such that the carrier is fixed inside the container 3.
- Separation membrane and separation filter May be provided.
- a cytokine-inducing agent immobilized on a carrier such as a particulate, fibrous, or non-woven fabric is provided in a blood bag having an introduction portion and an outlet portion. Fill and introduce blood or blood components into it. Thereafter, the blood is induced to incubate at a predetermined temperature for a predetermined time, and the blood or blood components from which the cytokine has been induced is taken out from the outlet portion, and can be used for a cytokine induction therapy or the like by infusion or the like.
- the method for inducing cytokines using the device for inducing cytokines of the present invention is also one of the present invention.
- the site force induction induced by the sitekine induction tool or method of the present invention is not particularly limited, but interferon y (IFN- ⁇ ), interleukin 10 (IL-10) are particularly preferable. And tumor necrosis factor- ⁇ (TNF- ⁇ ).
- IFN- ⁇ interferon y
- IL-10 interleukin 10
- TNF- ⁇ tumor necrosis factor- ⁇
- IFN- is a site that plays a very important role in various diseases, such as allergic diseases and cancer, and has a therapeutic effect on these diseases by inducing IFN- ⁇ . Can be expected.
- the cells capable of producing cytokines in the device and method for inducing cytokines of the present invention include various cells capable of producing blood, blood components, and cytokines.
- Cells collected from tissues such as myeloid cells, dendritic cells, epidermal cells, fibroblasts, hepatocytes, osteoblasts, blood stem cells, embryonic stem cells, etc. Refers to cells containing cultured cells, cell lines, and various cells that produce cytokines.
- the blood in the cytokine-inducing device and the cytokine-inducing method of the present invention of the present invention refers to blood or blood obtained by diluting blood or blood with an appropriate diluent, for example, a physiological saline solution, a medium, or a buffer.
- an appropriate diluent for example, a physiological saline solution, a medium, or a buffer.
- the blood components in the cytokine-inducing device and cytokine-inducing method of the present invention include not only leukocytes and platelets separated from blood, but also myeloid cells, dendritic cells, blood stem cells, blood cell-derived cell lines, and the like. Refers to what is contained. These may be used alone, or may be used by mixing leukocytes and the like separately collected with blood and the like. Further, these cells may be diluted with an appropriate diluent, for example, a physiological saline, a medium, a buffer, or the like, and used in the present invention, but blood is preferably used.
- an appropriate diluent for example, a physiological saline, a medium, a buffer, or the like
- FIG. 1 is a schematic cross-sectional view showing an example of the sitekine guiding tool of the present invention.
- the IFN- "V in human plasma was measured using an ELISA kit manufactured by R & D Systems, an ELISA kit manufactured by ENDOGEN, or an ELISA kit manufactured by Japan Antibody Research Institute.
- Carrier 1 manufactured by Organo, trade name: Amberlite XAD4, porous polystyrene particles, MR type, pore distribution 2 to 150 A, surface area 70 Omg or more, pore volume 0.5 mL / g or more, average Purified water with a pore size of about 12 OA) (Otsuka Pharmaceutical Co., Ltd.), followed by decantation, followed by decantation with methanol (Wako Pure Chemical Industries, HPLC).
- the carrier 1 was washed with decantation with saline for injection (manufactured by Otsuka Pharmaceutical Co., Ltd.), and the carrier 1 with a particle volume of 50 ⁇ L was sterilized in a tube (Etpendorf tube 1 manufactured by Diatron). .5 mL).
- Blood was collected from a healthy person to obtain venous blood containing 15 IU / mL heparin.
- BCG manufactured by Japan BCG Manufacturing Co., Ltd.
- BCG was prepared with physiological saline. At this time, the volume of the physiological saline was adjusted to 1.25 ° / 0 with respect to the blood.
- the tube was mixed by inversion and the blood was agitated, attached to a rotary mixer (manufactured by TAI TEC), and incubated at 37 ° C. for 24 hours in a thermostat while being inverted at 6 rpm.
- the blood was centrifuged at 4500C for 3 minutes at 3500 rpm (Tomie Seie Co., Ltd., micro high-speed centrifuge MR X-150), and then plasma was collected.
- the plasma was stored frozen.
- the stored plasma was thawed, and the amount of IFN- ⁇ induction in plasma was measured using a Human IFN-y ELISA kit (manufactured by R & D Systems or ENDOGEN).
- Table 1 Immediately after collecting the blood of the used healthy human and after culturing the blood alone in the same manner as described above, the value of IFN- ⁇ in the plasma was all 10 pg / mL or less.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 1 except that Carrier 1 was not used, and 1.5 mL of blood to which 80% was added was used. Was. The results are shown in Table 1.
- the amount of IFN-1 / induction was measured in the same manner as in Example 1 except that the carrier 1 was not used and 1.5 mL of blood without 0 was used. The results are shown in Table 1.
- the amount of IFN-V induction was measured in the same manner as in Example 1 except that BCG was not added to blood. The results are shown in Table 1.
- Carrier 1 to Carrier 2 manufactured by Organo, product name: Amberlite XAD 16 HP, polystyrene porous particles, MR type, pore distribution 2 to 300 A, surface area 80 OmsZg or more, pore volume 0.58 to 0
- the amount of induced IFN-y was measured in the same manner as in Example 1 except that the amount was changed to 6.5 mL / g and the average pore diameter was about 15 OA). The results are shown in Table 1.
- the amount of IFN- y induction was measured in the same manner as in Example 2 except that BCG was not added to blood. The results are shown in Table 1.
- Carrier 1 was converted to Carrier 3 (manufactured by Organo, trade name: Amberlite XAD 2000, polystyrene porous particles, MR type, pore distribution 2 to 80 A, surface area about 620 mg, pore volume about 0.7 mL) / g, and the average pore diameter was changed to about 40 to 50 A), except that the amount of induced IFN_Y was measured in the same manner as in Example 1. The results are shown in Table 1.
- Example 4 The amount of IFN- ⁇ induction was measured in the same manner as in Example 3 except that BCG was not added to blood. The results are shown in Table 1. (Example 4)
- Carrier 1 to Carrier 4 manufactured by Organo, trade name: Amberlite XAD 7HP, acrylic acid-based porous particles, MR type, pore distribution 2 to 200 ⁇ , surface area 400 mg or more, pore volume 0.5
- the amount of IFN-y induction was measured in the same manner as in Example 1 except that the average pore size was changed to at least ML / g and the average pore diameter was changed to about 400 to 500 A). The results are shown in Table 1.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 4 except that BCG was not added to blood. The results are shown in Table 1.
- I FN was prepared in the same manner as in Example 1 except that Polysciences (trade name) was used as the carrier, except that Poly 1ybeads Polystyrene Microsphere (particle size: 500-600 ⁇ m, non-porous) was used. — The amount of ⁇ induction was measured. The results are shown in Table 1.
- the amount of IFN- ⁇ induction was determined in the same manner as in Example 1 except that spherical polystyrene particles (styrenedivinylbenzene copolymer, particle size: 250-750 zm, non-porous) manufactured by Moritex were used as the carrier. Was measured. The results are shown in Table 1.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 1 except that spherical polymethyl methacrylate particles (particle size: 750-1 000 ⁇ , non-porous) manufactured by Moritex were used as the carrier. .
- the results are shown in Table 1.
- IFN- ⁇ was obtained in the same manner as in Comparative Example 3, except that spherical polystyrene particles (styrene-divinylbenzene copolymer, particle size 250-750 ⁇ , non-porous) manufactured by Moritex were used as the carrier. The amount of induction was measured. The results are shown in Table 1.
- the amount of IFN- ⁇ induction was measured in the same manner as in Comparative Example 3, except that spherical polymethyl methacrylate particles (particle size: 750 to 1,000 ⁇ m, nonporous) manufactured by Moritex were used as the carrier. did. The results are shown in Table 1.
- the values of IF F- ⁇ in plasma were all 10 pg / mL or less.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 5, except that Carrier 1 was not used, and 1.5 mL of OK-432 added blood was used. Table 2 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 5, except that Carrier 1 was not used, and 1.5 mL of 43-432-free blood was used. Table 2 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 5, except that ⁇ -432 was not added to the blood. Table 2 shows the results.
- Carrier 1 to Carrier 2 manufactured by Organo, trade name: Amberlite XAD 16
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 6, except that ⁇ -432 was not added to the blood. Table 2 shows the results.
- Carrier 1 was replaced by Carrier 3 (manufactured by Organo, trade name: Amberlite XAD 20000, polystyrene porous particles, MR type, pore distribution 2 to 8 ⁇ , surface area: about 620 m2 / g, pore volume: about 0.7 m
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 5 except that L / g and the average pore diameter were changed to about 40 to 50 A). Table 2 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 7, except that OK-432 was not added to the blood. Table 2 shows the results.
- Carrier 1 was replaced with Carrier 4 (manufactured by Organo, trade name: Amberlite XAD 7HH, acrylic acid-based porous particles, MR type, pore distribution 2 to 2000 A, surface area 40 OmS / Zg or more, pore volume 0.
- the IFN- ⁇ induction amount was measured in the same manner as in Example 5, except that the average pore diameter was changed to 5 mL / g or more and the average pore diameter was changed to about 400 to 500 A). Table 2 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 8, except that ⁇ -432 was not added to the blood. Table 2 shows the results.
- Example 9 The same procedure as in Example 5 was carried out, except that Polysciences (trade name) was used as a carrier, and the carrier was Poly1ybeads Polystyrene Microsphere (particle size: 500-600 ⁇ m, non-porous). The amount of IFN-y induction was measured. Table 2 shows the results.
- Example 5 The same procedure as in Example 5 was carried out except that spherical polymethyl methacrylate 1 and particles (particle size: 7500-1000 / zm, non-porous) manufactured by Moritex were used as carriers. The amount of ⁇ induction was measured. Table 2 shows the results.
- Carrier 1 (Amberlite XAD-4, manufactured by Organo Co., Ltd.) 1 mL of bulk volume and 1 mL of BCG (1 Omg / mL) were mixed in physiological saline at 37 ° C for 20 hours, and BCG was added to the carrier. The particles were physically adsorbed on the particle surface. After mixing, Carrier 1 was sufficiently washed with physiological saline and suspended in physiological saline. The thus obtained bulk volume 100 // L carrier 1 was filled in a sterilized tube. Hereinafter, the same operation as in Example 1 was performed except that 1.4 mL of blood was added to this tube, and the amount of induced I ⁇ "-was measured using the blood of a healthy person. The results are shown in Table 3. .
- the IFN- ⁇ value in the plasma was 10 pg / mL or less.
- Example 9 The same operation as in Example 9 was performed except that the carrier 1 was changed to the carrier 2 (Amberlite XAD 16 HP, manufactured by Organo), and the amount of induction of IFN- ⁇ was measured using blood of a healthy person. Table 3 shows the results.
- Example 9 The same operation as in Example 9 was performed except that the carrier 1 was changed to the carrier 3 (Amberlite XAD2000, manufactured by Organo), and the amount of induction of IFN- ⁇ was measured from blood of a healthy person. Table 3 shows the results.
- Example 9 The same operation as in Example 9 was performed except that the carrier 1 was replaced with the carrier 4 (Amberlite XAD7HP, manufactured by Organo), and the amount of induction of IFN- ⁇ was measured using blood of a healthy person. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 9 except that the carrier was not used and 1.5 mL of the 80-0 added blood was used. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 9, except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 10, except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- Example 11 The amount of IFN-y induction was measured in the same manner as in Example 11 except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results. (Comparative Example 2 9)
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 12, except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- IFN- ⁇ induction amount in the same manner as in Example 9 except that Polysciences (trade name) was used as the carrier: P o 1 ybeads Polystyrene Microsphere (500-600 ⁇ m in diameter, non-porous). was measured. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 9 except that spherical polymethylmetharylate particles (particle size: 750-1 000 ⁇ , non-porous) manufactured by Moritex were used as the carrier. did. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Comparative Example 30 except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Comparative Example 31 except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Comparative Example 32, except that a carrier to which BCG was not physically adsorbed was used. Table 3 shows the results.
- a sterilized tube 1.5 mL for Diatron, Inc.
- Example 11 The same operation as in Example 1 was performed, except that BCG alone was not added, and 1.4 mL of blood was added, and the amount of induction of IFN- ⁇ was measured. The results are shown in Table 11.
- the amount of induced IFN- ⁇ was measured in the same manner as in Example 13 except that Carrier 1 was not used, and 1 to 5 mL of BCG-added (1 mg / mL) blood was used. did.
- Example 13 Except for using Polysciences (trade name): P o 1 ybeads Polystyrene Microsphere (3 ⁇ 4A particle diameter 500-600 im, non-porous) as the carrier, the same procedure as in Example 13 was carried out. The amount of FN- ⁇ induction was measured. Table 4 shows the results.
- IFN- ⁇ Induction of IFN- ⁇ was carried out in the same manner as in Example 13 except that spherical polystyrene particles (styrene divinylbenzene copolymer, particle size: 250-750 ⁇ , non-porous) manufactured by Moritetutas were used as the carrier. The amount was measured. Table 4 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 13 except that spherical polymethyl methacrylate particles (particle size: 750-1000 / xm, non-porous) manufactured by Moritex were used as the carrier. did. Table 4 shows the results. Table 4
- a blood bag (for 50 mL capacity) was filled with a carrier 1 having a bulk volume of 4 mL in which the carrier 1 prepared in the same manner as in Example 13 and having BCG physically adsorbed on the particle surface was used.
- 50 mL of venous blood containing 15 IU / mL heparin obtained by collecting blood from a healthy person was introduced into this blood bag.
- the blood bag was incubated at 37 ° C. for 24 hours with gentle stirring.
- the amount of IFN- ⁇ induction in this blood was measured in the same manner as in Example 1. Table 5 shows the results.
- the value of IFN- ⁇ in the plasma was all 10 pgZmL or less.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 14 except that the carrier 1 in which BCG had not been subjected to a physical adsorption treatment was used. Table 5 shows the results.
- the amount of IFN- ⁇ induction was measured in the same manner as in Example 14 except that carrier 1 was not used and 5 OmL of blood supplemented with lmg / mL of BCG was used. Table 5 shows the results.
- IFN- ⁇ Induction of IFN- ⁇ was carried out in the same manner as in Example 14 except that spherical polystyrene particles (styrene-divinylbenzene copolymer, particle diameter 250-750 ⁇ , non-porous) manufactured by Moritex were used as the carrier. The amount was measured. Table 5 shows the results.
- BCG was suspended in physiological saline, diluted with a phosphate buffer, and centrifuged at 4000 rpm for 15 minutes. The supernatant was discarded, suspended again in a phosphate buffer, and centrifuged at 4000 rpm for 15 minutes. Perform this 3 times, then suspend in 50% ethanol-containing phosphate buffer, and centrifuge for 15 minutes at 4000 rpm (TMX Seiko Co., Ltd., micro high-speed centrifuge MR X-150). went. Then suspend in ethanol and at 4000 rpm Centrifugation was performed for 15 minutes. This was performed twice, and washing with a phosphate buffer solution was performed again three times.
- Example 6 The same operation as in Example 1 was performed except that BCG alone was not added, and the amount of blood added was 1.4 mL, and the amount of induction of IFN-y was measured. The results are shown in Table 6.
- Example 15 The same operation as in Example 15 was carried out except that BCG was not covalently bound, and the amount of induction of IFN- ⁇ was measured. The results are shown in Table 6.
- the amount of induced IFN- ⁇ was measured in the same manner as in Example 15 except that carrier 1 was not used and 1.5 mL of blood supplemented with 1 mg / mL of BCG was used. .
- P Olysciences trade name as a carrier P o 1 ybeads P olystyrene M icrosphere ( particle tens size 500 - 600 / m s non-porous) was used instead of in the same manner as in Example 1 5 I FN — The amount of ⁇ induction was measured. The results are shown in Table 6. Table 6
- 0.8 mL in bulk volume of the carrier 1 prepared by physically adsorbing BCG on the particle surface prepared in the same manner as in Example 13 was filled in a blood bag (for 5 mL capacity).
- 5 mL of venous blood containing 15 IU / mL heparin obtained by collecting blood from a healthy subject was introduced into this blood bag.
- the blood bag was incubated at 37 ° C for 24 hours with gentle agitation.
- the amount of TNF- ⁇ induction in the blood was measured in the same manner as in Example 1 except that a human TNF-H assay kit manufactured by ENDOGEN was used. The results are shown in Table 7.
- the TNF- ⁇ value in the plasma was all 16 pgZmL or less.
- a carrier in which BCG prepared in the same manner as in Example 13 was physically adsorbed on the particle surface 0.8 mL of 1 was filled in a blood bag (for 5 mL capacity). 5 mL of venous blood containing 15 IU / mL heparin obtained by collecting blood from a healthy subject was introduced into this blood bag. The blood bag was incubated at 37 ° C for 24 hours with gentle agitation. The amount of IL-10 induced in the blood was measured in the same manner as in Example 1 except that a human IL-10 measurement kit manufactured by ENDOGEN was used. Table 8 shows the results. Immediately after collecting the blood of the used healthy human and after culturing the blood alone in the same manner as described above, all the IL-10 values in the plasma were 15 pg / mL or less.
- the amount of induced IL-10 was measured in the same manner as in Example 17 except that the carrier 1 in which BCG had not been physically adsorbed was used. Table 8 shows the results. Table 8
- the carrier 1 prepared in the same manner as in Example 13 and in which BCG was physically adsorbed on the particle surface was added in a bulk volume of 0.1 mL to a 24-well multiplate (manufactured by Kojung).
- Spleen cells were collected from C 3 HZHe mice (8-week-old, female, purchased from Japan SLC) aseptically as possible and placed in RPMI medium (containing 2% fetal bovine serum) to a concentration of 500,000 cells / m. Prepared. 1.5 mL of this spleen cell suspension was added to each well of the multiplate, and cultured at 37 ° C under 5% carbon dioxide.
- the sitekine-inducing tool and the sitekine-inducing method of the present invention are an epoch-making method capable of inducing a practical level of cytokine in the presence of a water-insoluble porous material carrier using a cytokine inducer. It can induce much higher levels of cytokines than the typical c- cytokine inducer alone, and can be suitably used for the treatment of various diseases for which cytokines are effective. Further, the site force inducing tool and the site cytokine inducing method of the present invention induce the site force in by contacting blood and blood components outside the body. After removal of cytokine inducers that may cause side effects after induction, they can be used for treatment.
- the device for inducing cytokines and the method for inducing cytokines of the present invention can be suitably used for treating various diseases in which cytokine induction is effective.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005505898A JPWO2004096275A1 (ja) | 2003-04-28 | 2004-04-26 | サイトカイン誘導用具及びサイトカイン誘導方法 |
EP04729501A EP1618892A1 (en) | 2003-04-28 | 2004-04-26 | Instrument for inducing cytokine and method of inducing cytokine |
US10/555,068 US20060263430A1 (en) | 2003-04-28 | 2004-04-26 | instrument for inducing cytokine and method of inducing cytokine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-124340 | 2003-04-28 | ||
JP2003124340 | 2003-04-28 | ||
JP2003-124345 | 2003-04-28 | ||
JP2003124345 | 2003-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004096275A1 true WO2004096275A1 (ja) | 2004-11-11 |
Family
ID=33422072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005986 WO2004096275A1 (ja) | 2003-04-28 | 2004-04-26 | サイトカイン誘導用具及びサイトカイン誘導方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060263430A1 (ja) |
EP (1) | EP1618892A1 (ja) |
JP (1) | JPWO2004096275A1 (ja) |
WO (1) | WO2004096275A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60120821A (ja) * | 1983-12-05 | 1985-06-28 | Asahi Chem Ind Co Ltd | 悪性腫瘍治療用白血球刺激材および刺激方法 |
JPS61100522A (ja) * | 1984-10-24 | 1986-05-19 | Toray Ind Inc | 抗腫瘍性血液製剤の製造法 |
JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
JPS63160578A (ja) * | 1986-12-24 | 1988-07-04 | Asahi Chem Ind Co Ltd | 抗腫瘍キラ−t細胞の誘導方法 |
JPS63203623A (ja) * | 1987-02-20 | 1988-08-23 | Toray Ind Inc | 血液処理剤 |
JPH06209992A (ja) * | 1992-11-26 | 1994-08-02 | Sekisui Chem Co Ltd | 腫瘍壊死因子産生誘導方法 |
WO2003037375A1 (fr) * | 2001-11-02 | 2003-05-08 | Sekisui Chemical Co., Ltd. | Substance d'induction de cytokine et instrument d'induction de cytokine |
-
2004
- 2004-04-26 EP EP04729501A patent/EP1618892A1/en not_active Withdrawn
- 2004-04-26 US US10/555,068 patent/US20060263430A1/en not_active Abandoned
- 2004-04-26 WO PCT/JP2004/005986 patent/WO2004096275A1/ja not_active Application Discontinuation
- 2004-04-26 JP JP2005505898A patent/JPWO2004096275A1/ja not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60120821A (ja) * | 1983-12-05 | 1985-06-28 | Asahi Chem Ind Co Ltd | 悪性腫瘍治療用白血球刺激材および刺激方法 |
JPS61100522A (ja) * | 1984-10-24 | 1986-05-19 | Toray Ind Inc | 抗腫瘍性血液製剤の製造法 |
JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
JPS63160578A (ja) * | 1986-12-24 | 1988-07-04 | Asahi Chem Ind Co Ltd | 抗腫瘍キラ−t細胞の誘導方法 |
JPS63203623A (ja) * | 1987-02-20 | 1988-08-23 | Toray Ind Inc | 血液処理剤 |
JPH06209992A (ja) * | 1992-11-26 | 1994-08-02 | Sekisui Chem Co Ltd | 腫瘍壊死因子産生誘導方法 |
WO2003037375A1 (fr) * | 2001-11-02 | 2003-05-08 | Sekisui Chemical Co., Ltd. | Substance d'induction de cytokine et instrument d'induction de cytokine |
Non-Patent Citations (7)
Title |
---|
ABE Y. ET AL.: "The endogenous induction of tumor necrosis factor serum (TNS) for adjuvant postoperative immunotherapy of cancer.- changes in immunological markers of the blood-", JAPANESE JOURNAL OF SURGERY, vol. 20, no. 1, 1990, pages 19 - 26, XP002964353 * |
FUJIMOTO T. ET AL.: "Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state", J. IMMUNOL., vol. 158, no. 12, 1997, pages 5619 - 5626, XP002964356 * |
HAYASHI A.: "Gan men'eki ryoho no atarashii tenkai - shoki men'eki to kakutoku men'eki no kakehashi to shite no BCG-CWS", MOLECULAR MEDICINE, vol. 36, no. SPECIAL EXTRA ISSUE, 1999, pages 220 - 229, XP002964354 * |
RYOMA Y.: "A New Approach and Recent Advances in Action Mechanisms of OK-432 (picibanil)", BIOTHERAPY, vol. 14, no. 9, 2000, pages 877 - 885, XP002964355 * |
SHINMURA K. ET AL.: "Somen sakusan cellulose beads no shuyo eshi inshi yuki sayo", THE JAPANESE JOURNAL OF ARTIFICIAL ORGANS, vol. 22, no. 5, 1993, pages 1233 - 1237, XP002964358 * |
WILKINSON K.A. ET AL.: "Enhancement of the huan T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres", J. IMMUNOL. METHODS, vol. 235, no. 1-2, 2000, pages 1 - 9, XP004188226 * |
YAMAZAKI K. ET AL.: "Shushu no kobunshi oyobi hyomen arasa o yusuru zairyo ni okeru zen kecchu no karyukyu kyuchaku kyodo no kento", POLYMER PREPRINTS, vol. 40, no. 7, 1991, JAPAN, pages 2230 - 2232, XP002984765 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004096275A1 (ja) | 2006-07-13 |
US20060263430A1 (en) | 2006-11-23 |
EP1618892A1 (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2811073C (en) | Size selective polymer system | |
EP2981308B1 (en) | Hemocompatibility modifiers for cross-linked polymeric material | |
KR20040104615A (ko) | 개선된 분리법 | |
JP2023130402A (ja) | 内毒素血症誘発分子を除去するための血液適合性多孔質ポリマービーズ収着材の使用 | |
JP2618497B2 (ja) | 腫瘍障害細胞誘導剤および腫瘍障害細胞誘導デバイス | |
Maeda et al. | Influence of administration of mesenchymal stromal cell on pediatric oxygenator performance and inflammatory response | |
JPS61277628A (ja) | 癌治療用白血球刺激材 | |
WO2004096275A1 (ja) | サイトカイン誘導用具及びサイトカイン誘導方法 | |
JPH0622633B2 (ja) | 吸着体およびそれを用いた除去装置 | |
JP2006192271A (ja) | ウイルスおよびウイルス成分を液体、特に血液および血漿から除去するための吸着系 | |
US20050013791A1 (en) | Cytokine-inducing material and cytokine-inducing instrument | |
US8932854B2 (en) | Adsorbent for lymphocyte proliferation inhibitor and treating method | |
Wang et al. | Macroporous poly (vinyl alcohol) microspheres bearing phosphate groups as a new adsorbent for low-density lipoprotein apheresis | |
JPH0611333B2 (ja) | 免疫複合体の吸着体およびそれを用いた免疫複合体の除去装置 | |
JP2007217360A (ja) | 免疫活性増強された細胞または細胞由来成分の製造方法、免疫活性増強材料及び免疫活性増強器具 | |
JP2004323484A (ja) | サイトカイン誘導材料及びサイトカイン誘導用具 | |
JPS6229524A (ja) | 悪性腫瘍治療用刺激剤 | |
JP2991721B2 (ja) | 抗甲状腺刺激ホルモンレセプター抗体の吸着体とそれを用いた抗甲状腺刺激ホルモンレセプター抗体の除去装置 | |
WO2004096247A1 (ja) | サイトカイン誘導用具及びサイトカイン誘導方法 | |
JPS63160578A (ja) | 抗腫瘍キラ−t細胞の誘導方法 | |
JPH0316639A (ja) | 吸着体およびそれを用いた除去装置 | |
JP3313854B2 (ja) | Tnf産生誘導材料 | |
WO2006106763A1 (ja) | リンパ球増殖抑制因子の除去方法 | |
JP2003201251A (ja) | サイトカイン誘導材料及びサイトカイン誘導用具 | |
JP6814632B2 (ja) | 顆粒球除去方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505898 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004729501 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004729501 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006263430 Country of ref document: US Ref document number: 10555068 Country of ref document: US |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 10555068 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004729501 Country of ref document: EP |